Core Insights - atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing effective mental health treatments to improve patient outcomes [2] Group 1: Company Overview - atai's pipeline includes psychedelic-based therapies such as VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, both currently in Phase 2 clinical development [2] - The company is also working on a drug discovery program aimed at identifying novel, non-hallucinogenic 5-HT2AR agonists for TRD [2] - atai aims to provide scalable interventional psychiatry therapies that can be integrated into healthcare systems [2] Group 2: Upcoming Events - The management team is scheduled to participate in the Jefferies Global Healthcare Conference and the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference in June [1] - Webcasts of the fireside chats will be available on the Investors section of the atai website, with replays accessible after the live events [1][3] - Specific dates for the fireside chats include June 5 at 9:55 A.M. EDT and June 17 at 7:00 A.M. EDT [3]

Company Overview - Atai Life Sciences N.V. (ATAI) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Price Performance - ATAI shares have increased by 18.71% over the past week, significantly outperforming the Zacks Medical - Outpatient and Home Healthcare industry, which rose by 1.81% during the same period [6] - Over the past month, ATAI's stock price has risen by 32.03%, compared to the industry's 2.96% [6] - In the last quarter, ATAI shares increased by 22.42%, and over the past year, they gained 23.93%, while the S&P 500 experienced a decline of -2.55% and a modest increase of 11.45%, respectively [7] Trading Volume - The average 20-day trading volume for ATAI is 1,976,396 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, three earnings estimates for ATAI have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$0.75 to -$0.60 [10] - For the next fiscal year, two estimates have moved upwards, while one has been revised downwards [10] Conclusion - Given the strong price performance, positive earnings outlook, and high Momentum Style Score, ATAI is recommended as a solid momentum pick for investors [12]

Technical Analysis - Atai Life Sciences N.V. (ATAI) has reached a significant support level, indicating a potential investment opportunity from a technical perspective [1] - A "golden cross" has occurred, with ATAI's 50-day simple moving average breaking above its 200-day moving average, suggesting a potential bullish breakout [1] Market Performance - ATAI has experienced a rally of 25.7% over the past four weeks, indicating strong market performance [3] - The company currently holds a 2 (Buy) rating on the Zacks Rank, further supporting the bullish outlook [3] Earnings Expectations - There have been three upward revisions in earnings expectations for the current quarter, with no downward revisions over the past 60 days, indicating positive sentiment among analysts [3] - The Zacks Consensus Estimate for earnings has also increased, reinforcing the bullish trend [3][4] Investment Outlook - The combination of positive earnings estimate revisions and the technical breakout suggests that investors should monitor ATAI for potential gains in the near future [4]

Group 1 - atai Life Sciences N.V. (ATAI) is outperforming its peers in the Medical sector with a year-to-date return of approximately 43.6%, while the average return for Medical companies is -6.3% [4] - The Zacks Rank for atai Life Sciences N.V. is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings outlooks [3] - The Zacks Consensus Estimate for ATAI's full-year earnings has increased by 0.8% over the past quarter, reflecting improved analyst sentiment [4] Group 2 - atai Life Sciences N.V. is part of the Medical - Outpatient and Home Healthcare industry, which ranks 84 in the Zacks Industry Rank, and this industry has an average year-to-date return of 3.7% [6] - Cardinal Health (CAH), another stock in the Medical sector, has a year-to-date return of 29.6% and also holds a Zacks Rank of 2 (Buy) [5] - The Medical - Dental Supplies industry, to which Cardinal Health belongs, is currently ranked 42 and has experienced a year-to-date decline of -1% [7]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and... Read more Abou ...

- BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours after dosing A single dose of BPL-003 induced rapid and long-lasting antidepressant effects, with a mean MADRS (Montgomery-Asberg Depression Rating Scale) reduction of 18 points from baseline observed the day after dosing, a mean MADRS reduction of 19 points from baseline observed one month after dosing, and a mean MADRS reduction of 18 points from baseline observed three months after dosing. T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-40493 ATAI Life Sciences N.V. (Exact name of registrant as specified in its charter) The Netherlands Not Ap ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company is focused on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - Automation and software tools, including generative AI, are used, but all content is edited and authored by humans [5]

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates Exhibit 99.1 With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Cash, cash equivalents, short-term securities, and public equity holdings expected to fund operations into 2027 NEW YORK and BERLIN, May 14, 2025 – atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a ...